Lipid profile, serum malondialdehyde, superoxide dismutase in chronic kidney diseases and type 2 diabetes mellitus

Biomedical Research

Volumn 23, Issue 2, 2012, Pages 207-210

  Padalkar, Ramchandra K ^a   Shinde, Ashok V ^b   Patil, Sangita M ^a  

^a Department of Biochemistry   (India)

^b SINHGAD DENTAL COLLEGE AND HOSPITAL   (India)

Author keywords

Chronic kidney disease (ckd); Malondialdehyde; Superoxide dismutase

Indexed keywords

CHOLESTEROL; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LIPID; LOW DENSITY LIPOPROTEIN CHOLESTEROL; MALONALDEHYDE; SUPEROXIDE DISMUTASE; TRIACYLGLYCEROL; VERY LOW DENSITY LIPOPROTEIN CHOLESTEROL;

ADULT; AGED; ARTICLE; BLOOD SAMPLING; CHOLESTEROL BLOOD LEVEL; CHRONIC KIDNEY DISEASE; CONTROLLED STUDY; DIET RESTRICTION; ENZYME ACTIVITY; ENZYME BLOOD LEVEL; FEMALE; HUMAN; HYPERTRIGLYCERIDEMIA; LIPID ANALYSIS; LIPID PEROXIDATION; MAJOR CLINICAL STUDY; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; OXIDATIVE STRESS; TRIACYLGLYCEROL BLOOD LEVEL;

EID: 84860176750     PISSN: 0970938X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (22)

1. Lwington S, Whit lock G, Clarke R, Sherlinker P, Embersan J, Halsey J et al. Blood cholesterol and vascular mortality by age sex and blood pressure a meta analysis of individual data from 61 prospective studies with 55,000 vascular death. Lancet 2007; 370: 1829-1839.
2. Vaziri ND, Moradi H. Mechanism of dislipidemia of chronic renal failure. Inter J Haemodialysis 2006; 10 (3): 1-7.
3. Halliwell B, Gutteridge JM. Free radical antioxidant and human disease, where are we now? J Lab Clin Med 1992; 119: 598-620.
4. Haffner SM, Lehto S, Ronnemaa T, Pyorala K, Laakso M. Mortality from coronary heart disease in subject with type 2 diabetes and in non diabetic subjects with and without prior myocardial infarction. N Engl J Med 1998; 339: 229-234.
5. Irshed M, Chaudhari PS. Oxidant and Anti Oxidant System: Role and significance in human body. Indian J Exp Biol 2002; 40: 1233-1239.
6. Report of the expert committee on the diagnosis and classification of diabetes mellitus. Diabetes care 2003; 26 (Suppl): 15-20.
7. Friedwald WT, Levy RI, Fredrickson DS. Estimation of the concentration of low density lipoprotein cholesterol in plasma without the use of the preparative ultra centrifuge. Clin Chem 1992; 18: 499-502.
8. Wilbur KM, Bernhei MF, Shapiro OW. The thiobarbituric acid method for malondialdehyde estimation. Arch. Biochem. Biophysics 1943; 250: 305-313
9. Marklund S, Marklund GA. Simple assay for super oxide dismutase using autooxidation of pyrogallol. Eur J Biochem 1974; 47: 469-472.
10. Kes P. Lipid abnormalities in CRF, nephrotic syndrome and dialysis. Acta Med Crotica 2001; 55 (4-5): 177-186.
11. Sharma BK, Jindal SK, Rana DS, Gupta B, Kumar M. Absence of hyperlipedemia patients of chronic renal failure in Chandigarh. Ind. J. Med. Res. 1980; 72: 461-464.
12. Alam SM, Bhatt AK. Abnormal lipoproteins in uremic patients treated conservatively and by maintenance hemodialysis. JAPI 1991; 39: 170-172.
13. A Rao, AR Bitta, EP Reddy, Sivakumar V, Rao R. Lipid abnormalities, Lipoprotein (a) and apoprotein pattern in non dialyzed patients with chronic kidney disease. Indian J Clin Biochem 2010; 25: 47-50.
14. Attman PO, Samuelson O, Alaupovic P. Lipoprotein metabolism and renal failure. Am J Kidney Dis 1993; 21: 573-592.
15. Vaziri ND. Dyslipidemia of chronic renal failure the nature, mechanism and potential consequences. Am J Renal. Physiology 2006; 290 (2): 262-272.
16. De boer IH, Astor BC, Kramer H, Palmas W, Seliger SL, Shlipak MJ. et.al. Lipoprotein abnormalities associated with mild impairment of kidney function in the multi ethic study of atherosclerosis. J Am Soc Nephrology 2008; 3: 125-132.
17. Vaziri ND, Liang K, Parks JS. Down regulation of hepatic lecithin: cholesterol acyltransferase, Gene expression in chronic renal failure. Kidney Int 2001; 59: 2192-2196.
18. Hansel B, Giral P, Nobecourt E, Chantepie S, Bruckert E, Chapman MJ. Metabolic syndrome is associated with elevated oxidative stress and dysfunctional dense high density lipoprotein particles displaying impaired antioxidative activity. J Clin Endocrinal Metabolism 2004; 89: 4963-4971.
19. Kastelein JJ, Ordovas JM, Wittekoek MF, Pimstona S., Wilson WF. Gange S.F. Two common mutations in lipoprotein lipase: a cumulative analysis of their Influence on plasma lipid and lipoproteins in men and women. Clinical Genetics 1999; 56: 297-305.
20. De Zwart LL, Meerman JH, Commondeur JN, Vermeolen NP: Biomarkers of free radical damage applications in experimental animals and in humans. Free radical Biol Med 1999; 26: 202-226.
21. Seghrouchni J, Drani J, Bannier F, Riviere J, Calmard P et al. Oxidative stress parameters in type 1, type 2 an insulin treated diabetes mellitus, insulin treatment efficiency. Clin Chim Acta 2002; 321: 89-96.
22. Dominguez C, Rniz E, Gossinye M, Carrascosa A, Oxidative stress at onset and in early stage of type 1 diabetes in children and adolescents. Diabetes Care 1998; 21:1736-1742.